Zobrazeno 1 - 7
of 7
pro vyhledávání: '"33"'
Autor:
Ravi Kushwaha, M.R. Behera, Vikas Agarwal, Jithu Kurian, Monika Yacha, Amit Gupta, Vinita Agrawal, Manoj Jain, Narayan Prasad, Dharmendra Bhadauria
Publikováno v:
Lupus. 29:845-853
IntroductionLupus nephritis (LN) has a considerable impact on the morbidity and mortality of systemic lupus erythematosus (SLE) patients. Long-term comparative outcome data from the Indian subcontinent on treatment regimens with cyclophosphamide (CYP
Publikováno v:
Lupus. 22:1135-1141
Objective The objective of this paper is to evaluate the efficacy of combined mycophenolate mofetil (MMF) and tacrolimus (TAC) for lupus nephritis with suboptimal response to standard therapy. Methods Inclusion criteria for patients: (1) biopsy-confi
Publikováno v:
Lupus. 14:129-136
The antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) in patients with thromboembolic complications. In APS, most aPL are autoantibodies to β2-glycoprotein I and prothrombin, which play a major rol
Autor:
Omer Karadag, Yahya Buyukasik, Ali Akdogan, Levent Kilic, Sedat Kiraz, İsmail Doğan, Umit Akman, Şule Apraş Bilgen, Ihsan Ertenli
Publikováno v:
Lupus. 22(8)
Systemic lupus erythematosus (SLE) patients are at increased risk of thrombosis and cardiovascular diseases. Aspirin is an effective treatment option for these patients. The aim of this study was to investigate the presence of aspirin resistance in S
Autor:
Han Ls, Lin Zhang, Zhangsuo Liu, Hui Li, Yu-Jie He, Guanmin Gao, Xinyou Zhang, Xuejun Zeng, Zhaohui Zheng, Shengyun Liu, Jinyan Guo
Publikováno v:
Lupus. 22(5)
Our objective was to determine metabolic syndrome (MS) prevalence in Chinese patients with systemic lupus erythematosus (SLE) and to investigate the conditions that contribute to its development. 116 patients with SLE classified according to the Amer
Publikováno v:
Lupus. 16(2)
Seventy-two patients with antiphospholipid antibodies (aPL), with or without antiphospholipid syndrome (APS), were studied for detection of heparin-PF4-induced antibodies (HPIA) using a commercial kit (Asserachrom® HPIA) PF4-dependant enzyme-linked
Autor:
Juan Carlos Reverter, Ricard Cervera, F. J. Muñoz-Rodriguez, Josep Font, Gerard Espinosa, Francisco Carmona, Juan Balasch, Dolors Tàssies, Antonio Ordinas, Miguel Ingelmo
Publikováno v:
Lupus. 11(11)
Antiphospholipid antibodies (aPL) may induce acquired activated protein C resistance (acquired APCR). The role of acquired APCR in patients with systemic lupus erythematosus (SLE) is not well known. To evaluate the prevalenceof acquiredAPCR and its a